etrials Worldwide Names E. James Emerson, Ph.D., As Vice President of Technology and Development

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services designed to optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, announced today that E. James (Jim) Emerson, Ph.D. has been named as the Company�s vice president of technology and development.

"We believe Jim�s hands on approach, academic background and work in industry standards and best practices within complex data-intensive software environments makes him the right leader to implement our strategy to take a more accelerated approach to developing next generation eClinical technologies, while driving operational scale," said M. Denis Connaghan, etrials� president and chief executive officer.

"After being here for a few months on a consulting basis, I am honored by the confidence that Denis has placed in me and am excited to be joining etrials on a full-time basis," said Dr. Emerson. "I�m equally confident in etrials� products and their capabilities, and see a great deal of potential for additional previously unexplored opportunities for the Company to be opportunistic given the recent changes we�re seeing in the clinical trial market-place,� Dr. Emerson added. �As such, my priorities will be to ensure focus on developing new, innovative and viable products designed to drive quick and sustained revenue streams.�

Dr. Emerson brings an extensive background in the implementation of data base management systems. He has both the theoretical and real-world knowledge needed to effectively implement database applications and technology, having been an end-user of database management systems in various industry environments, as well as an executive with commercial software development organizations. Previously, Dr. Emerson has served as director of computer resources at KPMG in their New York executive office; vice president of technology at Pansophic Systems (now part of Computer Associates); president of RTI Software; and senior vice president at Marsh USA. An active member of industry and professional associations, Dr. Emerson is a member of ANSI/SPARC, CODASYL, ANSI X3H4, and ISO. He also was the Chairman of the Technology Information Committees of ADAPSO and ITAA.

E. James Emerson holds a Ph.D. in Computer Science from the New York Polytechnic Institute, a MBA from Seton Hall University and a B.S. in Physics from the University of Florida. Dr. Emerson has also served as a professor of data base management systems and SQL at North Central College in Naperville, IL.

About etrials(R)

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of eClinical software and services to pharmaceutical, biotechnology, medical device, and contract research organizations, offers adaptive, Web-based tools that work together to coordinate data capture, logistics, patient interaction and trial management - turning data into intelligence and shortening the pathway to an actionable study endpoint. etrials is one of the few top-tier solution providers that offers electronic data capture (EDC), interactive voice and Web response (IVR/IWR) and electronic patient diaries (eDiary) as part of a flexible and integrated software-as-a-service (SaaS) platform or as individual solutions to capture high quality data from multiple pivot points to enable real-time access for informed decision-making. As an experienced leader, etrials has facilitated over 900 trials involving more than 400,000 patients in 70 countries and has participated in 42 studies that resulted in 14 approved new drug applications and/or regulatory approvals. To learn more visit us at www.etrials.com. etwcf

Forward-Looking Statements

This announcement contains forward-looking statements, including statements regarding strategy and opportunities of the company, all of which involve risks and uncertainties. Actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to, reliance on key personnel, the current economic climate, delays in the current schedule for clinical trials by existing clients, utilization of our software and services by clients to a lesser degree than is currently expected and terminations of existing projects, all of which are possible because our client agreements generally do not have minimum volume guarantees and can be terminated without penalty by clients. Additionally, actual results might differ from those discussed due to failure to secure new project bookings at the same rate reported or that management currently expects. More information about potential factors that could cause actual results to differ from the forward looking statements included in this announcement is included in our filings with the Securities and Exchange Commission, including the "Risk Factors" Section of the Form 10-K for the year ended December 31, 2008. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements, except as required by law.

etrials(R) is the registered trademark in the United States of etrials Worldwide, Inc. Other marks belong to their respective owners and are used with permission.

Etrials Worldwide (MM) (NASDAQ:ETWC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024